SI2279206T1 - Metoda za preprečevanje razvoja revmatoidnega artritisa pri subjektih z nedifirenciranim artritisom - Google Patents

Metoda za preprečevanje razvoja revmatoidnega artritisa pri subjektih z nedifirenciranim artritisom

Info

Publication number
SI2279206T1
SI2279206T1 SI200931228T SI200931228T SI2279206T1 SI 2279206 T1 SI2279206 T1 SI 2279206T1 SI 200931228 T SI200931228 T SI 200931228T SI 200931228 T SI200931228 T SI 200931228T SI 2279206 T1 SI2279206 T1 SI 2279206T1
Authority
SI
Slovenia
Prior art keywords
arthritis
subjects
development
preventing
undifferentiated
Prior art date
Application number
SI200931228T
Other languages
English (en)
Slovenian (sl)
Inventor
George Vratsanos
Jean-Claude Becker
Michael Corbo
Original Assignee
Bristol-Myers Squibb Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41264941&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SI2279206(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bristol-Myers Squibb Company filed Critical Bristol-Myers Squibb Company
Publication of SI2279206T1 publication Critical patent/SI2279206T1/sl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/48—Ergoline derivatives, e.g. lysergic acid, ergotamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70521—CD28, CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Rheumatology (AREA)
  • Transplantation (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Saccharide Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
SI200931228T 2008-05-05 2009-05-05 Metoda za preprečevanje razvoja revmatoidnega artritisa pri subjektih z nedifirenciranim artritisom SI2279206T1 (sl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US5033608P 2008-05-05 2008-05-05
US12/387,359 US7915222B2 (en) 2008-05-05 2009-05-01 Method of preventing the development of rheumatoid arthritis in subjects with undifferentiated arthritis
PCT/US2009/042761 WO2009137424A1 (en) 2008-05-05 2009-05-05 Method of preventing the development of rheumatoid arthritis in subjects with undifferentiated arthritis
EP20090743410 EP2279206B1 (en) 2008-05-05 2009-05-05 Method of preventing the development of rheumatoid arthritis in subjects with undifferentiated arthritis

Publications (1)

Publication Number Publication Date
SI2279206T1 true SI2279206T1 (sl) 2015-08-31

Family

ID=41264941

Family Applications (1)

Application Number Title Priority Date Filing Date
SI200931228T SI2279206T1 (sl) 2008-05-05 2009-05-05 Metoda za preprečevanje razvoja revmatoidnega artritisa pri subjektih z nedifirenciranim artritisom

Country Status (25)

Country Link
US (3) US7915222B2 (enExample)
EP (2) EP2279206B1 (enExample)
JP (1) JP2011522795A (enExample)
KR (1) KR20110014180A (enExample)
CN (1) CN102037010A (enExample)
AR (1) AR071672A1 (enExample)
AU (1) AU2009244448B2 (enExample)
BR (1) BRPI0912249A2 (enExample)
CA (1) CA2723698C (enExample)
CL (1) CL2009001082A1 (enExample)
DK (1) DK2279206T3 (enExample)
EA (1) EA201001749A1 (enExample)
ES (1) ES2539840T3 (enExample)
HK (1) HK1208230A1 (enExample)
HR (1) HRP20150552T1 (enExample)
HU (1) HUE025256T2 (enExample)
IL (1) IL208691A (enExample)
MX (1) MX2010011503A (enExample)
NZ (1) NZ589020A (enExample)
PL (1) PL2279206T3 (enExample)
PT (1) PT2279206E (enExample)
SI (1) SI2279206T1 (enExample)
TW (2) TWI454278B (enExample)
WO (1) WO2009137424A1 (enExample)
ZA (1) ZA201007914B (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040022787A1 (en) 2000-07-03 2004-02-05 Robert Cohen Methods for treating an autoimmune disease using a soluble CTLA4 molecule and a DMARD or NSAID
US7915222B2 (en) 2008-05-05 2011-03-29 Bristol-Myers Squibb Company Method of preventing the development of rheumatoid arthritis in subjects with undifferentiated arthritis
CN103906767A (zh) * 2011-10-10 2014-07-02 米迪缪尼有限公司 对类风湿关节炎的治疗
US20140006055A1 (en) * 2012-06-27 2014-01-02 Iagnosis, Inc. Integrated Medical Evaluation and Record Keeping System
US20150232558A1 (en) * 2012-10-30 2015-08-20 Emory University Stimulating bone formation by inhibition of cd28 co-stimulation
WO2014151230A2 (en) * 2013-03-15 2014-09-25 Bristol-Myers Squibb Company Method of treating granulomatosis with polyangiitis
WO2015164595A1 (en) * 2014-04-25 2015-10-29 Bristol-Myers Squibb Company Use of ctla4 compound for achieving drug-free remission in subjects with early ra
SMT202100467T1 (it) 2015-04-17 2021-09-14 Alpine Immune Sciences Inc Proteine immunomodulatorie con affinità regolabili
AU2017248830B2 (en) 2016-04-15 2023-03-09 Alpine Immune Sciences, Inc. CD80 variant immunomodulatory proteins and uses thereof
EP3491013A1 (en) 2016-07-28 2019-06-05 Alpine Immune Sciences, Inc. Cd155 variant immunomodulatory proteins and uses thereof
EP3694870A1 (en) 2017-10-10 2020-08-19 Alpine Immune Sciences, Inc. Ctla-4 variant immunomodulatory proteins and uses thereof
SG11202006148UA (en) 2018-01-03 2020-07-29 Alpine Immune Sciences Inc Multi-domain immunomodulatory proteins and methods of use thereof
CN110148465B (zh) * 2019-05-10 2023-07-04 中山大学孙逸仙纪念医院 一种用于分析类风湿性关节炎的系统
US12202882B2 (en) 2020-05-08 2025-01-21 Alpine Immune Sciences, Inc. APRIL and BAFF inhibitory immunomodulatory proteins and methods of use thereof

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7070776B1 (en) * 1990-03-26 2006-07-04 Bristol-Myers Squibb Company Methods for blocking binding of CD28 receptor to B7
US6641809B1 (en) * 1990-03-26 2003-11-04 Bristol-Myers Squibb Company Method of regulating cellular processes mediated by B7 and CD28
DE69226871T3 (de) * 1991-06-27 2009-09-24 Bristol-Myers Squibb Co. CTL4A-Rezeptor, ihn enthaltenden Fusionsproteine und deren Verwendung
US5844095A (en) * 1991-06-27 1998-12-01 Bristol-Myers Squibb Company CTLA4 Ig fusion proteins
US6090914A (en) * 1991-06-27 2000-07-18 Bristol-Myers Squibb Company CTLA4/CD28Ig hybrid fusion proteins and uses thereof
US5770197A (en) * 1991-06-27 1998-06-23 Bristol-Myers Squibb Company Methods for regulating the immune response using B7 binding molecules and IL4-binding molecules
US5851795A (en) * 1991-06-27 1998-12-22 Bristol-Myers Squibb Company Soluble CTLA4 molecules and uses thereof
EP0683793A4 (en) * 1993-01-21 1997-04-09 Univ Georgia Res Found VACCINE AND METHODS FOR PREVENTION AND TREATMENT OF Fescue Toxicity In Herbivorous Animals.
US5773253A (en) * 1993-01-22 1998-06-30 Bristol-Myers Squibb Company MYPPPY variants of CTL A4 and uses thereof
US6750334B1 (en) * 1996-02-02 2004-06-15 Repligen Corporation CTLA4-immunoglobulin fusion proteins having modified effector functions and uses therefor
ATE219376T1 (de) * 1996-03-20 2002-07-15 Bristol Myers Squibb Co Verfahren zur inhibierung der immunreaktion durch blockierung der gp39/cd40 und ctla4/cd28/b7 routen und zusammensetzung zu deren verwendung
US20030219863A1 (en) * 1997-01-31 2003-11-27 Bristol-Myers Squibb Company Soluble CTLA4 mutant molecules and uses thereof
ZA98533B (en) * 1997-01-31 1999-07-22 Bristol Myers Squibb Co Soluble CTLA4 mutant molecules and uses thereof.
US7094874B2 (en) * 2000-05-26 2006-08-22 Bristol-Myers Squibb Co. Soluble CTLA4 mutant molecules
MXPA02012157A (es) * 2000-06-09 2003-06-06 Bristol Myers Squibb Co Metodos para regular una respuesta inmune mediada por celulas al bloquear se°ales linfociticas y al bloquear la adhesion mediada por el antigeno 1 asociado con la funcion de linfocitos.
US20040022787A1 (en) * 2000-07-03 2004-02-05 Robert Cohen Methods for treating an autoimmune disease using a soluble CTLA4 molecule and a DMARD or NSAID
CA2630062C (en) * 2000-07-03 2014-10-14 Bristol-Myers Squibb Company Methods for treating graft versus host disease and immune disorders associated with rejection using a soluble ctla4 molecule
MXPA03006699A (es) * 2001-01-26 2004-05-31 Univ Emory Metodos de induccion de tolerancia al trasplante de organos y correccion de hemoglobinopatias.
ATE390931T1 (de) * 2001-05-23 2008-04-15 Bristol Myers Squibb Co Verfahren zum schützen eines allogenen inseltransplantats mit löslichen ctla4- mutationsmolekülen
TWI328614B (en) * 2002-12-23 2010-08-11 Bristol Myers Squibb Co Product quality enhancement in mammalian cell culture processes for protein production
EP1575998A4 (en) * 2002-12-23 2007-07-25 Bristol Myers Squibb Co PROCESS FOR CULTIVATING MAMMALIAN CELLS FOR PROTEIN PRODUCTION
NZ545314A (en) * 2003-08-04 2009-03-31 Bristol Myers Squibb Co Methods for treating cardiovascular disease using a soluble CTLA4 molecule
US10092429B2 (en) * 2005-08-22 2018-10-09 Incept, Llc Flared stents and apparatus and methods for delivering them
ATE498358T1 (de) 2005-06-29 2011-03-15 Compumedics Ltd Sensoranordnung mit leitfähiger brücke
PT2253644E (pt) 2005-12-20 2014-01-23 Bristol Myers Squibb Co Composições e métodos para a produção de uma composição
TW200738261A (en) 2005-12-20 2007-10-16 Bristol Myers Squibb Co Stable protein formulations
US7528111B2 (en) * 2006-05-12 2009-05-05 Bristol-Myers Squibb Company Method of vaccinating subjects receiving immune modulating therapy
US7915222B2 (en) * 2008-05-05 2011-03-29 Bristol-Myers Squibb Company Method of preventing the development of rheumatoid arthritis in subjects with undifferentiated arthritis

Also Published As

Publication number Publication date
CN102037010A (zh) 2011-04-27
WO2009137424A1 (en) 2009-11-12
EP2891665A1 (en) 2015-07-08
TWI454278B (zh) 2014-10-01
TW201444575A (zh) 2014-12-01
HUE025256T2 (en) 2016-02-29
KR20110014180A (ko) 2011-02-10
TW200948381A (en) 2009-12-01
HK1148291A1 (en) 2011-09-02
US9012408B2 (en) 2015-04-21
DK2279206T3 (en) 2015-07-27
EP2279206A4 (en) 2011-05-25
PL2279206T3 (pl) 2015-09-30
BRPI0912249A2 (pt) 2015-10-20
US20090280119A1 (en) 2009-11-12
US20110142835A1 (en) 2011-06-16
EP2279206B1 (en) 2015-04-22
JP2011522795A (ja) 2011-08-04
US7915222B2 (en) 2011-03-29
AU2009244448B2 (en) 2014-07-31
US20130195865A1 (en) 2013-08-01
CA2723698A1 (en) 2009-11-12
HK1208230A1 (en) 2016-02-26
AU2009244448A1 (en) 2009-11-12
EP2279206A1 (en) 2011-02-02
MX2010011503A (es) 2010-11-09
AR071672A1 (es) 2010-07-07
ZA201007914B (en) 2011-07-27
EA201001749A1 (ru) 2011-06-30
PT2279206E (pt) 2015-07-27
CA2723698C (en) 2018-03-06
CL2009001082A1 (es) 2010-02-12
ES2539840T3 (es) 2015-07-06
NZ589020A (en) 2012-05-25
US8435952B2 (en) 2013-05-07
IL208691A0 (en) 2010-12-30
IL208691A (en) 2015-01-29
HRP20150552T1 (hr) 2015-06-19

Similar Documents

Publication Publication Date Title
IL208691A0 (en) Method of preventing the development of rheumatoid arthritis in subjects with undifferentiated arthritis
IL244197A0 (en) Antibodies against cd100 and methods of using them
EP2508487A4 (en) WASTEWATER PRETREATMENT METHOD AND EFFLUENT TREATMENT METHOD USING THE PRETREATMENT PROCESS
IL250624B (en) Anti-fgfr3 antibodies and methods of using them
EP2262038A4 (en) Cell selector and cell with it
HUE066432T2 (hu) Szeparátor és az azt tartalmazó elektrokémiai berendezés
EP2164981A4 (en) METHODS AND DEVICES FOR DETERMINING ANALYTES
SI2209805T1 (sl) Antigen, povezan z revmatoidnim artritisom
PL2394156T3 (pl) Układ i sposób do pomiaru elektrochemicznego reakcji biochemicznych jak też sposób wytworzenia takiego układu
LT2417158T (lt) Dkk-1 antikūnai
EP2343759A4 (en) BATTERY COMPONENT AND BATTERY
AP2011005536A0 (en) Treatment of rheumatoid arthritis with mammal betadefensins.
GB0903151D0 (en) Antibody uses and methods
IL219136A0 (en) Anti-hepsin antibodies and methods using same
FI20095020L (fi) Menetelmä aukirullaimen yhteydessä
IL216389A0 (en) Solar field and method for assembling the solar field
TWI372256B (en) Test apparature and test method
TWI373159B (en) Electrolyte for electrochemical device and the electrochemical device thereof
GB0822140D0 (en) Methods and reagents
PL2103942T3 (pl) Sposób określania charakteru zapalnej choroby reumatycznej w płynie maziowym
GB0707069D0 (en) Methods and uses
EP2185685A4 (en) NEW PROCESSES AND NEW CELL LINES
GB0816523D0 (en) Methods and uses
GB0810609D0 (en) Methods and uses
GB0819611D0 (en) Electrochemical cells and components thereof